Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
TVRD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
Current
Estimates
Sales Growth
Current
Estimates
Return on Equity
QoQ
Q3.24
NA
NA
vs 0.07
Institutionnal Ownership
businesswire.com
7 hours ago
businesswire.com
8 hours ago
businesswire.com
16 hours ago
globenewswire.com
16 hours ago
Quote Panel
Key Metrics
Relative Strength
TVRD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
NASDAQ
1.01 ( 4.71%)
Relative Strenght
Volume Buzz
-67%
Earning Acce
No
Dist 52w H.
35%Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
78.00(247.28%)
Number of analyst
1
Last analyst upgrade/downgrade
Piper Sandler
initialisePrevious: Not converted
2025-06-12
Now: Overweight
Oppenheimer
initialisePrevious: Not converted
2025-05-21
Now: Outperform
BTIG
initialisePrevious: Not converted
2025-05-15
Now: Buy
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How TVRD compares to sector?
TVRD
-12x